Ricciardi Luisa, Soler Daniel Griscti, Bennici Alessandra, Brunetto Silvia, Pioggia Giovanni, Gangemi Sebastiano
Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, Policlinico "G. Martino", University of Messina, Messina, Italy.
Institute for Biomedical Reasearch and Innovation, National Research Council of Italy (IRIB-CNR), Messina, Italy.
Front Pharmacol. 2022 Apr 7;13:858344. doi: 10.3389/fphar.2022.858344. eCollection 2022.
Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a major player in the pathogenesis of EGPA. In 2017 the Food and Drug Administration (FDA) approved mepolizumab, a humanized monoclonal antibody targeting interleukin 5 (IL-5) which reduces the production and survival of eosinophils, already used to treat severe eosinophilic asthma, for the management of EGPA. Benralizumab is a humanized monoclonal antibody that targets the IL-5 receptor and is indicated in the treatment of severe eosinophilic asthma. We describe the case of a young female with a positive history of severe eosinophilic asthma associated with EGPA, treated successfully with benralizumab.
传统上，嗜酸性肉芽肿性多血管炎（EGPA）一直采用全身糖皮质激素和免疫抑制剂进行治疗。近年来，治疗工作已转向针对嗜酸性粒细胞，嗜酸性粒细胞是EGPA发病机制中的主要参与者。2017年，美国食品药品监督管理局（FDA）批准了美泊利单抗，这是一种靶向白细胞介素5（IL-5）的人源化单克隆抗体，可减少嗜酸性粒细胞的产生和存活，该药物已用于治疗严重嗜酸性粒细胞性哮喘，现被批准用于EGPA的治疗。贝那利珠单抗是一种靶向IL-5受体的人源化单克隆抗体，用于治疗严重嗜酸性粒细胞性哮喘。我们描述了一名年轻女性的病例，她有严重嗜酸性粒细胞性哮喘合并EGPA的病史，使用贝那利珠单抗治疗成功。
